Antitumor host immunity enhanced by near‐infrared photoimmunotherapy
Cancer Science · 2025-03 · 116 (3) · 572-580
DOI: 10.1111/cas.16427 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 12.12.2024. Verfasst von Hiroshi Fukushima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Phototherapy, Infrared Rays. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, CCR NIH HHS, Center for Cancer Research.
Abstract (Originalsprache)
Near‐infrared photoimmunotherapy (NIR‐PIT) is a novel antitumor therapy that selectively kills cancer cells by NIR light‐triggered photochemical reaction of IRDye700DX within Ab–photoabsorber conjugates (APCs). NIR‐PIT induces immunogenic cell death, causing immune cell migration between the tumor and tumor‐draining lymph nodes, and expanding multiclonal tumor‐infiltrating CD8 + T cells. Crucially, the cytotoxic effects of NIR‐PIT are limited to cancer cells, sparing immune cells such as antigen‐presenting cells and T cells, which are key players in boosting antitumor host immunity. By modifying the Ab used in APC synthesis, NIR‐PIT can be repurposed to target and deplete noncancerous immunosuppressive cells including regulatory T cells, myeloid‐derived suppressor cells, and cancer‐associated fibroblasts in the tumor microenvironment. Immunosuppressive cell targeted NIR‐PIT strongly potentiates antitumor host immunity, including the induction of abscopal effects and the development of immune memory. Furthermore, antitumor immune responses and therapeutic efficacy are synergistically enhanced when NIR‐PIT is combined with other immune‐activating treatments, such as interleukin‐15 and immune checkpoint inhibitors. These new findings make NIR‐PIT a valuable tool in the evolving landscape of cancer immunotherapy. This review explains the role of NIR‐PIT in activating antitumor host immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
- Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
- Department of Head and Neck Surgery, Institute of Science Tokyo, Tokyo, Japan.
ORCID-Profile: Hiroshi Fukushima, Aki Furusawa, Ryuhei Okada, Yasuhisa Fujii, Hisataka Kobayashi
Förderung
- Intramural NIH HHS
- CCR NIH HHS
- Center for Cancer Research
Zitieren
APA
Fukushima, H., Furusawa, A., Okada, R., Fujii, Y., Choyke, P. L., & Kobayashi, H. (2025). Antitumor host immunity enhanced by near‐infrared photoimmunotherapy. Cancer Science, 116(3), 572-580. https://doi.org/10.1111/cas.16427
Vancouver
Fukushima H, Furusawa A, Okada R, Fujii Y, Choyke PL, Kobayashi H. Antitumor host immunity enhanced by near‐infrared photoimmunotherapy. Cancer Science. 2025;116(3):572-580. doi:10.1111/cas.16427
BibTeX
@article{Fukushima2025,
author = {Fukushima, Hiroshi and Furusawa, Aki and Okada, Ryuhei and Fujii, Yasuhisa and Choyke, Peter L and Kobayashi, Hisataka},
title = {Antitumor host immunity enhanced by near‐infrared photoimmunotherapy},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {3},
pages = {572--580},
doi = {10.1111/cas.16427}
}
EUVIMED